EAST WALPOLE, Mass., March 4 /PRNewswire/ -- InSet Technologies announced that an application for CE Mark was filed for the Prometra(TM) Implantable, Programmable Pump System. In conjunction, the Design Dossier for the proprietary pump system has been submitted to the notified body for review and approval. InSet Technologies anticipates approval during the second quarter of 2004.
The Prometra(TM) Implantable, Programmable Pump System is based upon proprietary technology capable of delivering a wide array of therapeutic compounds.
"The CE mark application is an important step in bringing the Prometra(TM) Implantable, Programmable Pump System to the market," said Mr. Jonathan Donaldson, President of InSet Technologies. "This unique pump offers significant advantages over existing technologies and will make a significant difference in patient care. We are very excited about this filing and the progress it represents for the treatment of chronic pain," said Donaldson.
InSet Technologies, an InfuMedics Inc. company, markets a range of proprietary implantable pump technology, including the Fluent(TM) Constant Flow Pump, which received its CE mark in June 2003.
For more information, contact: Warren Pelissier Acom* Healthcare (781) 749-9290 wep@acomhealthcare.com
InSet TechnologiesCONTACT: Warren Pelissier of Acom* Healthcare, +1-781-749-9290,wep@acomhealthcare.com
